Executing strategic partnerships to advance BioAge's lead programs in obesity and metabolic aging, and to discover drugs against novel targets for chronic diseases of aging.Originated and signed a Phase 2 clinical trial collaboration with Eli Lilly to determine if the combination of azelaprag and tirzepatide will increase total weight loss and improve body composition in obese subjects. Collaboration facilitated $170M Series D financing.Executed partnerships to discover drug candidates which modulate novel BioAge metabolic aging targets.

BioAge is a clinical-stage biotechnology company that is harnessing the biology of human aging to develop novel targets and therapies for age-related diseases, based on novel insights from its discovery platform built on human longevity data. Led BioAge’s efforts to identify and execute strategic transactions to convert prioritized drug targets into a portfolio of therapies for treating severe diseases of aging. Responsibilities included business development, strategy, market assessment, and finance. Licensed rights from Amgen to BioAge's lead program, Azelaprag, which modulates a key aging mechanism identified by BioAge’s propriety human aging dataset.Raised $90M Series C to fund clinical trials and build pipeline.

Helping biotech companies to develop strategy and execute partnership and financing transactions. Retained to evaluate financing options, and refine research focus and partnering strategy.

Shasqi's Click Activated Protodrug Platform activates powerful cytotoxic drugs precisely at tumors to eradicate cancer while reducing toxic side effects. Worked with senior management and board to define research strategy. Championed the development of improved antibody directed (ADC) therapeutics.

Engine Biosciences has a unique Computational / Machine Learning Platform that is tightly coupled with wet-lab validation using a proprietary high throughput CRISPR-based screen. Worked with management team and advisors to define research strategy. Championed in-licensing strategy successfully executed by competitors in synthetic lethality.

Developed and operationalized a strategy to build, through in-licensing, a clinical-stage pipeline of novel therapies that can be specifically targeted to treat cancer patients poorly served by existing treatments. Licensed Paxalisib from Genentech now in Phase 3 for treating advanced brain cancers.

Acquired commercialization rights for products to treat cardiovascular disease and endocrine disorders.

Acquired commercialization rights for approved products for Asia Pacific or across regions globally through licensing, joint ventures, asset purchase or M&A. Focus therapeutics areas were diabetes, cardiovascular, endocrinology, and oncology. .

Led transaction origination and execution in the Biotechnology Sector. Participated in the purchase of over $600mm in royalty assets derived from leading pharmaceutical products in 2012. In 2012, developed and executed innovative royalty acceleration transaction structure to allow companies to receive royalty payments over a defined shorter period and recognize payments as income that would otherwise have been received over the full term of the license agreement.

Executed Transactions including IPOs, Equity Capital Raises, Debt Offerings, M&A

Executed Transactions including IPOs, Equity Capital Raises, Debt Offerings, M&A

Cancer biology and target validation.- Led oncology drug development project from discovery to lead candidate stage- Primary inventor for patent in the Inflammatory Disease area (Treatment of TNF-alpha-mediated disorders with Casein Kinase I epsilon inhibitors WO 2004035076 A1)